DuckWiseDuckWise Get the app

Archive › NVAX

NVAX trade ideas: every closed DuckWise idea on Novavax, Inc.

DuckWise has published 1 idea on Novavax, Inc. (NVAX, Stock) that has closed between October 2021 and November 2021. Each is listed below with the levels published before the position was taken and its result at close — 1 in profit, 0 at a loss.

1closed idea
1 / 0in profit / at a loss
+20.26%average result
23 daystypical holding period
OpenedClosedSideEntryStopProjectionCloseResultDays
Oct 11, 2021Nov 3, 2021Long167.27—195201.16+20.26%23

Prices in US dollars. Prices are as traded on the day. Result is the price change from the published entry to the published close plus dividends received while the idea was held (paid, for shorts), before fees, taxes and slippage. How results are counted.

NVAX questions and answers

Has DuckWise published trade ideas on NVAX?

Yes. DuckWise has published 1 idea on Novavax, Inc. (NVAX) that closed between October 2021 and November 2021: 1 closed in profit and 0 at a loss. The average result was +20.26% from the published entry to the published close, dividends included.

What was the latest closed DuckWise idea on NVAX?

A long idea opened on October 11, 2021 with an entry of $167.27 and a price projection of $195.00. It closed on November 3, 2021 at $201.16, a result of +20.26% after 23 days.

How long did DuckWise hold its NVAX ideas?

The typical NVAX idea was held about 23 days from entry to close. DuckWise ideas are swing and position trades, not day trades.

Is there an open DuckWise idea on NVAX right now?

Not at the moment. When DuckWise publishes a new idea on NVAX, app subscribers get a push notification; it appears on this page once it closes.

Is this page a stock forecast for NVAX or a recommendation to buy it?

No. This page records closed ideas only. Each price projection was a published level for a model idea, not a forecast of where NVAX will trade. The research is general and impersonal, not a recommendation to buy or sell NVAX or any other security.

More trade ideas on the record

Every ticker in the archive · Track record by year

About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. Does not pay dividends.

These are closed ideas, published for the record. They are general and impersonal research, not a recommendation to buy or sell NVAX or any other security.